Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · August 27, 2022

Glucose Level–Lowering Effects and Safety of Low vs Standard Dose of Lobeglitazone in Patients With T2D With Inadequate Control on Metformin and DPP4 Therapy

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study
Diabetes Obes Metab 2022 Sep 01;24(9)1800-1809, S Ryang, SS Kim, JC Bae, JM Han, SK Kwon, YI Kim, IS Nam-Goong, ES Kim, MK Kim, CW Lee, S Yoo, G Koh, MJ Kwon, JH Park, IJ Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading